Adamis Pharmaceuticals Provides Update for Naloxone Product Candidate
SAN DIEGO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today the completion of pharmacokinetic (PK) studies comparing its naloxone injection product candidate, ZIMHITM (naloxone) Injection, to a generic …